eligibility_summary
Inclusion: Adults 18–75 with advanced/metastatic NSCLC (IIIb–IV), progressed after PD‑1/L1 ± platinum chemo, measurable disease, ECOG 0–1, ≥12‑week survival, adequate organ function, nonsquamous EGFR/ALK/ROS1‑negative, contraception required. Exclusion: prior topo‑I or TROP2 therapy, severe irAEs, >10% SCLC/neuroendocrine, active CNS mets, uncontrolled pain/effusions, recent therapy/surgery, other cancers <5y, ILD/TB/infection, major CV disease, bleeding, thrombosis, uncontrolled HTN, autoimmune/HIV, HBV/HCV, live vaccine, unresolved AEs, severe allergy, other risks.
trial_source
clinical_trials.gov from Dec 2, 2025
annotation_status
ai
ai_summary
Trial: Phase II, single-arm study in advanced/metastatic NSCLC after failure of standard first-line therapy. Interventions and mechanisms: • SHR-A1921: TROP2-targeted antibody–drug conjugate (ADC). Binds TROP2 on tumor cells, is internalized, and releases a cytotoxic topoisomerase I inhibitor payload, causing DNA damage, replication stress, and tumor cell death (with potential bystander effect). Drug type: ADC with topo I inhibitor payload. • Adebrelimab: anti–PD-L1 monoclonal antibody (immune checkpoint inhibitor). Blocks PD-L1 from engaging PD-1, restoring T-cell activation and cytotoxic function in the tumor microenvironment. Cells/pathways targeted: • TROP2-expressing NSCLC cells, DNA replication/topoisomerase I pathway. • PD-1/PD-L1 immune checkpoint on tumor and immune cells (APCs/T cells), enhancing antitumor T-cell responses.